Navigating Anthem (Elevance Health) Ultomiris Prior Authorization

Understanding Ultomiris and Anthem Prior Authorization Dynamics

Ultomiris (ravulizumab) is a C5 complement inhibitor indicated for rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). As a high-cost specialty medication, often administered via infusion, it consistently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans offered by Anthem-licensed entities. Effective management of this process is critical for patient access and financial stability.

Submission Channels for Ultomiris Prior Authorizations with Anthem

For Ultomiris, typically billed under the medical benefit, prior authorization requests are primarily submitted to Anthem-licensed plans through Availity Essentials, Anthem's primary multi-payer provider workspace. This portal facilitates PA initiation, member benefit lookups, and document uploads. Additionally, X12 278 transactions are supported via clearinghouses for electronic submission for impacted procedures.

Key Submission Pathways for Ultomiris

• **Availity Essentials:** Anthem's primary provider portal for medical benefit prior authorizations, including specialty drugs like Ultomiris.
• **X12 278 Transactions:** Electronic submission through your clearinghouse for medical benefit PA requests, aligning with industry standards.
• **Carelon Medical Benefits Management:** While Ultomiris typically routes through standard medical PA, always verify if specific therapeutic categories or site-of-care requirements fall under Carelon MBM's scope, as they operate a distinct submission portal for certain services.

Accessing Ultomiris Medical Policies and Clinical Criteria

Anthem operating companies publish medical policies and clinical utilization management guidelines through provider sites accessible via Availity. These resources outline the specific medical necessity criteria for Ultomiris. It is crucial to reference the policy number, specific plan-state context, and effective date, as criteria can vary and are aligned to Elevance Health's corporate framework with state-specific variants. For procedures routed through Carelon MBM, their clinical guidelines are published on the Carelon MBM provider site.

Common Denial Reasons and Appeal Pathways for Ultomiris with Anthem

Denials for Ultomiris prior authorizations from Anthem often stem from insufficient documentation, failure to meet medical necessity criteria, step therapy not completed (if applicable), or site-of-service mismatches given active Carelon site-of-care policies. Denials are communicated via X12 277/835 transactions and Availity status updates. For appeals, follow the Anthem operating-company appeals process detailed in the provider manual, with peer-to-peer review options available for both standard and Carelon MBM denials.

Klivira's Role in Streamlining Anthem Ultomiris Prior Authorization

Klivira integrates directly with EMRs and payer portals, including Anthem's Availity-based systems and X12 278 pathways, to automate critical steps in the Ultomiris prior authorization process. Our platform reduces manual burdens, enhances data accuracy, and helps accelerate decision times, improving patient access to vital therapies and optimizing revenue cycle performance.